ReviewWorld journal of urology2026
Salvage prostatectomy for locally recurrent prostate cancer after radiation: a narrative review of indications, outcomes, and surgical advancements.
Review in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSalvage prostatectomy (sRP) is one of several treatment options for localized prostate cancer recurrence after radiation. However, given the complexity of this operation, traditionally high complication rates, and poor functional outcomes, sRP has historically been underutilized. Herein, we aim to review the indications, outcomes, and technical advancements of sRP in modern practice.
methodsA literature review was performed using PubMed, Google Scholar, and Scopus for relevant articles that were synthesized in the current work.
resultsImprovements in interpretation of magnetic resonance imaging and increased adoption of molecular imaging can better detect local and oligometastatic recurrence. In combination with clinical variables, this can better select patients who may achieve a durable response from sRP. Ten-year biochemical recurrence-free survival after sRP ranges from 28 to 53%, with cancer specific survival ranging from 65 to 83%. While complication rates for sRP are higher than for primary prostatectomy, major complications, especially rectal injury, have decreased significantly. Erectile function is poor after sRP, although most studies report high rates of pre-operative impotence. Continence rates are highly variable (20-80%) secondary to heterogeneous reporting. Due to high rates of lymph node involvement, lymph node dissection should be performed with sRP and has prognostic value. Finally, robotic sRP is gaining popularity and may lead to improvements in continence, although further study is needed.
conclusionSalvage prostatectomy can achieve durable cancer control in a substantial group of patients. With improving complication rates and functional outcomes in experienced hands, sRP remains an important treatment for radio-recurrent prostate cancer.
Indexed as
Identifiers
42262568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.